About Us
- Ansaris has developed a proprietary platform technology that solves contemporary small molecule drug discovery challenges
- The Ansaris approach has identified novel drug candidates for previously intractable targets such as renin, for targets that have failed using high-throughput screening to generate progressible hits, and for targets that lack crystal structure
- The platform has been successfully applied to target classes such as kinases, proteases, phosphatases, and cell surface receptors in several therapeutic areas including oncology, inflammation, CV, and infectious disease
- The platform combines a torsion-space algorithm for building dynamic protein models with in silico fragment-based libraries and world-class computational chemists to design breakthrough therapeutics
- Our approach can enable the 'rescue' of stalled programs by identifying hotspots for protein-protein interactions, allosteric sites for enzymes, and functionally selective protein conformations